Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study

被引：6

作者：

Burger, R. ^{[1
]}

Brady, M. ^{[2
]}

Bookman, M. ^{[3
]}

Monk, B. ^{[4
]}

Walker, J. ^{[5
]}

Homesley, H. ^{[6
]}

Fowler, J. ^{[7
]}

Greer, B. ^{[8
]}

Boente, M. ^{[9
]}

Liang, S. ^{[10
]}

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[2] GOG Stat & Data Ctr, Buffalo, NY USA

[3] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA

[4] Creighton Univ, Sch Med, Phoenix, AZ USA

[5] Univ Oklahoma, Oklahoma City, OK USA

[6] Wake Forest Univ, Med Ctr, Winston Salem, NC USA

[7] Ohio State Univ, Columbus, OH 43210 USA

[8] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[9] Minnesota Oncol Hematol PA, Minneapolis, MN USA

[10] N Shore Univ Hosp, Manhasset, NY USA

来源：

关键词：

D O I：

10.1016/j.ygyno.2010.12.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S5 / S5

页数：1